Overview

Axoft is an implantable brain-computer interface company founded in 2021 in Cambridge, Massachusetts, and led by chief executive Paul Le Floch. Its platform is built on Fleuron, a polymer electrode material the company describes as up to 10,000 times softer than the polyimide used in existing implants. The bet is that softer materials can reduce the tissue response and signal loss that limit long-term implants.

Funding

Axoft closed an oversubscribed $55 million Series A on 29 April 2026, led by C.P. Group Innovation, the strategic investment arm of Thailand’s Charoen Pokphand conglomerate. Hillhouse Investment and Gaorong Ventures, both China-based, joined alongside Alumni Ventures and the Stanford President’s Venture Fund. Total funding is over $60 million. Axoft plans to use the money for global clinical trials, progress towards US regulatory approval and a good manufacturing practice facility.

Clinical work

With the round, Axoft disclosed an acute intraoperative test of its Fleuron probe in a patient at a Shanghai hospital: a 20-minute recording taken during another surgical procedure, with the probe removed afterwards. As of April 2026 it had tested Fleuron in more than 11 patients worldwide.

Why it matters

Axoft pairs a US regulatory route with a cap table led by Thai capital and including Chinese investors, plus clinical work in China. That mix puts it at the centre of questions about cross-border capital in implantable neurotechnology. Whether the Shanghai work moves to chronic implantation, and under which regulator, is the next signal.

Coverage on InsideBCI

• 29 April 2026: Axoft draws C.P. Group lead in $55M Series A as US BCI company runs first acute implant in Shanghai
• 10 May 2026: Thailand emerges as a BCI commercial corridor with C.P. Group connecting US and Chinese capability
• 30 April 2026: Former Harvard chemistry chair Charles Lieber leads state-funded Shenzhen BCI lab i-BRAIN